VYNE Therapeutics' Phase 2b Repibresib Gel Trial for Vitiligo Misses Primary Endpoint

VYNE Therapeutics announced topline results from its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The trial, involving 177 subje...
Home/KnloSights/Clinical Trial Updates/VYNE Therapeutics' Phase 2b Repibresib Gel Trial for Vitiligo Misses Primary Endpoint